All In Biotech

Free tool

FAERS Monitor: Trelstar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022437 or its brand name (Trelstar, Triptorelin Pamoate). Reports on generic versions are filed under their own applications.

Reports

2,599

Serious

1,873

72% of reports

Hospitalization

623

Death reported

532

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death406
  • fatigue128
  • hot flush127
  • inappropriate schedule of product administration110
  • off label use107
  • asthenia89
  • prostatic specific antigen increased89
  • malignant neoplasm progression82
  • product dose omission issue82
  • disease progression78
  • terminal state74
  • drug ineffective73
  • nausea70
  • dizziness63
  • fall63

Reports by year received

View as table
YearReports
20043
20055
20067
200716
20087
20095
201019
201133
201253
201328
201447
201570
201657
201758
2018138
2019157
2020221
2021205
2022251
2023268
2024331
2025383
2026237

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,560 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
terminal stateSignal7490.572.26,393
prostatic specific antigen increasedSignal8952.642.94,429
hot flushSignal12713.711.51,480
malignant neoplasm progressionSignal826.55.2376
disease progressionSignal785.34.3272
inappropriate schedule of product administrationSignal1104.94.1345
deathSignal4063.83.5876
product dose omission issueSignal822.31.857
asthenia891.91.639
fall631.51.211
fatigue1281.31.111
dizziness631.00.80
off label use1071.00.80
nausea700.70.68
drug ineffective730.40.452

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.